scispace - formally typeset
M

Michael A. Thompson

Researcher at Mayo Clinic

Publications -  232
Citations -  9329

Michael A. Thompson is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Brain-derived neurotrophic factor. The author has an hindex of 44, co-authored 226 publications receiving 7451 citations. Previous affiliations of Michael A. Thompson include University of Texas MD Anderson Cancer Center & Memorial Hospital of South Bend.

Papers
More filters
Journal ArticleDOI

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

Nicole M. Kuderer, +239 more
- 20 Jun 2020 - 
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.
Journal ArticleDOI

BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice.

TL;DR: It is shown that mutant mice with low levels of the spindle assembly checkpoint protein BubR1 develop progressive aneuploidy along with a variety of progeroid features, including short lifespan, cachectic dwarfism, lordokyphosis, cataracts, loss of subcutaneous fat and impaired wound healing.
Journal ArticleDOI

Effect of nanoparticle surface charge at the plasma membrane and beyond

TL;DR: It is demonstrated that the surface charge of gold nanoparticles (AuNPs) plays a critical role in modulating membrane potential of different malignant and nonmalignant cell types and subsequent downstream intracellular events.
Journal ArticleDOI

Regulation of intracellular levels of NAD: a novel role for CD38.

TL;DR: Tissue levels of NAD in CD38 deficient mice are 10- to 20-fold higher than in wild-type animals, and NADase activity in the plasma membrane, mitochondria, sarcoplasmic reticulum, and nuclei is essentially absent, which support the novel concept that CD38 is a major regulator of cellular NAD levels.